阿西米尼布用于复发或耐火的费城染色体阳性急性淋巴细胞白血病
Mathilde Chanut1, Aurélie Cabannes-Hamy1, Marie Balsat2
1Centre Hospitalier de Versailles, Le Chesnay, France.
Blood advances
|July 2, 2025
概括
阿西米尼布有效治疗复发的费城染色体阳性急性淋巴细胞白血病和慢性髓性白血病的淋巴细胞爆发危机. 与阿斯基米尼布的联合治疗改善了在这些具有挑战性的血液性恶性瘤中无事件生存率.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿西米尼布是一种全抑制剂,向BCR::ABL1基化位点.
- 复发的费城染色体阳性急性淋巴细胞白血病 (Ph+ ALL) 和慢性髓性白血病 (LBC-CML) 的淋巴细胞爆发危机代表了难以治疗的疾病.
研究的目的:
- 评估阿西米尼布在复发Ph+ALL和LBC-CML的患者中的疗效.
- 评估治疗结果,包括响应率和存活率,在接受asciminib的患者队列中.
主要方法:
- 对41名在法国接受阿西米尼布治疗的患者的回顾性分析.
- 阿西米尼布每天两次服用200毫克,单独或组合,主要作为第三线或后期治疗.
- 综合完整响应 (CR/CRi) 和可测量的残留疾病 (MRD) 负性的评估.
主要成果:
- 30/36个可评估患者实现了CR/CRi.
- 在分析的患者中,57%的患者获得了MRD阴性.
- 平均总生存期和无事件生存期分别为9.8个月和4.9个月.
- 与单一治疗相比,组合疗法显示改善了EFS (7.93 vs 4.23 个月).
- 在2名复发患者中发现了一种新的Q252H突变.
结论:
- 阿西米尼布显示出作为Ph+ALL和LBC-CML的有效救援疗法的承诺.
- 组合疗法可以提高这些患者群体的治疗结果.
- 对阿斯基米尼布的作用和耐药性机制的进一步研究是有必要的.
更多相关视频
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.3K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.5K
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K